Literature DB >> 16201927

Resistance to fluoroquinolones linked to gyrA and par C mutations and overexpression of acr AB efflux pump in Salmonella enterica serotype Choleraesuis.

Chishih Chu1, Lin-Hui Su, Chi-Hung Chu, Sylvie Baucheron, Axel Cloeckaert, Cheng-Hsun Chiu.   

Abstract

Between 2000 and 2002, 60 clinical isolates of Salmonella enterica serotype Choleraesuis were collected to investigate the mechanism of fluoroquinolone resistance. PCR and sequencing were performed to identify mutations in gyrA, gyrB, par C, the Acr AB-TolC efflux pump regulator, acr R, and the global regulons mar RAB and sox RS. All resistant strains showed mutations in the target genes leading to amino acid changes of Ser 83 Phe and Asp 87 Asn in GyrA and Ser 80 Ile in Par C. A mutation in gyrB was linked to the serotype genetic diversity but not to fluoroquinolone resistance. An efflux pump inhibitor, Phe-Arg-beta-naphthylamide, caused fourfold lower MIC of ciprofloxacin in the resistant isolates, indicating that efflux systems are involved in fluoroquinolone resistance. Western blot analysis showed moderate overproduction of Acr A in fluoroquinolone- resistant isolates. A mutation in acr R gave rise to an internal stop codon in both ciprofloxacin-resistant and -susceptible isolates, suggesting another serotype genetic diversity. No mutations were detected in mar RAB and sox RS among the isolates examined. Cross-resistance to three fluoroquinolones was observed, but gatifloxacin demonstrated relatively lower MICs than those of ciprofloxacin and levofloxacin. Fluoroquinolone resistance in S. Choleraesuis appears to be the combination effect of multiple mutations in various target genes and overexpression of the Acr AB-TolC efflux pump.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16201927     DOI: 10.1089/mdr.2005.11.248

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  8 in total

1.  Reverse engineering antibiotic sensitivity in a multidrug-resistant Pseudomonas aeruginosa isolate.

Authors:  Julie M Struble; Ryan T Gill
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

2.  The Global Regulatory Cyclic AMP Receptor Protein (CRP) Controls Multifactorial Fluoroquinolone Susceptibility in Salmonella enterica Serovar Typhimurium.

Authors:  Stefani C Kary; Joshua R K Yoneda; Stephen C Olshefsky; Laura A Stewart; Steven B West; Andrew D S Cameron
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

3.  Characterization of the multidrug efflux transporter styMdtM from Salmonella enterica serovar Typhi.

Authors:  Aqsa Shaheen; Fouzia Ismat; Mazhar Iqbal; Abdul Haque; Zaheer Ul-Haq; Osman Mirza; Rita De Zorzi; Thomas Walz; Moazur Rahman
Journal:  Proteins       Date:  2021-05-21

4.  Enhanced resistance to fluoroquinolones in laboratory-grown mutants & clinical isolates of Shigella due to synergism between efflux pump expression & mutations in quinolone resistance determining region.

Authors:  Neelam Taneja; Arti Mishra; Ajay Kumar; Garima Verma; Meera Sharma
Journal:  Indian J Med Res       Date:  2015-01       Impact factor: 2.375

Review 5.  Mechanism of action of and resistance to quinolones.

Authors:  Anna Fàbrega; Sergi Madurga; Ernest Giralt; Jordi Vila
Journal:  Microb Biotechnol       Date:  2008-10-13       Impact factor: 5.813

6.  PMQR genes oqxAB and aac(6')Ib-cr accelerate the development of fluoroquinolone resistance in Salmonella typhimurium.

Authors:  Marcus H Wong; Edward W Chan; Li Z Liu; Sheng Chen
Journal:  Front Microbiol       Date:  2014-10-02       Impact factor: 5.640

7.  ramR mutations affecting fluoroquinolone susceptibility in epidemic multidrug-resistant Salmonella enterica serovar Kentucky ST198.

Authors:  Sylvie Baucheron; Simon Le Hello; Benoît Doublet; Etienne Giraud; François-Xavier Weill; Axel Cloeckaert
Journal:  Front Microbiol       Date:  2013-07-31       Impact factor: 5.640

8.  Pharmacokinetic/Pharmacodynamic Integration to Evaluate the Changes in Susceptibility of Actinobacillus pleuropneumoniae After Repeated Administration of Danofloxacin.

Authors:  Longfei Zhang; Zheng Kang; Lihua Yao; Xiaoyan Gu; Zilong Huang; Qinren Cai; Xiangguang Shen; Huanzhong Ding
Journal:  Front Microbiol       Date:  2018-10-10       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.